About Us
Aerys Biosciences
About Us
Aerys Biosciences is a clinical-stage biopharmaceutical company advancing next-generation small-molecule therapies for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). Headquartered in Stanford Research Park (Palo Alto, California), Aerys operates at the heart of one of the world’s leading biomedical innovation hubs.
Our mission is to transform the treatment of fibro-inflammatory lung diseases by targeting the underlying mechanisms driving fibrosis and vascular remodeling. We bring together a multidisciplinary team of scientists, physicians, and clinical collaborators dedicated to translating our cutting-edge discoveries into therapies for patients with limited options.
Our Mission
Aerys Biosciences is committed to developing safe, effective, and innovative small-molecule therapies for fibro-inflammatory lung diseases. By targeting the biological drivers of fibrosis and vascular remodeling, we aim to deliver disease-modifying treatments that elevate standards of care for patients with pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), ultimately improving long-term outcomes.
Who We Are
Aerys Biosciences is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded by leading scientists and clinicians, we work as a bench-to-bedside team translating breakthrough research into impactful therapies for fibro-inflammatory lung diseases. Spun out of Stanford University and Greenstone Biosciences, we blend academic innovation with industry execution to advance next-generation small-molecule treatments for PAH and IPF.
Our Vision
We envision a future where fibro-inflammatory diseases no longer limit quality of life. Through new approach methodologies using human-relevant disease testing models, strategic collaboration, and patient-centered innovation, we strive to deliver transformative therapies that restore health and hope for those affected by pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), and related fibrotic conditions.
Why It Matters
Fibro-inflammatory lung diseases such as idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) are devastating, progressive conditions with limited effective treatment options, leading to declining lung function and reduced quality of life. At Aerys Biosciences, we are committed to changing this reality through the development of innovative small-molecule therapies that directly target the cellular and molecular drivers of fibrosis and vascular remodeling. Through pioneering discovery methods, human-relevant disease models, and early-stage clinical studies, we strive to redefine the standard of care and bring new hope to patients living with these life-limiting diseases.
